China Recovery Hints at What’s Next for Medtech

article image

As US medtech ponders its recovery from the COVID-19 pandemic, there are lessons to be learned from the early days of China’s rebound.

The first COVID-19 laden earnings season goes into full gear in early May, as companies report first-quarter results. Most US-focused companies only started to see notable damage from COVID-19 in mid-to-late March, so the numbers they report won’t reflect the depth of the damages. The consensus among experts is that medtech will take a much bigger hit in Q2, given the drop off in elective procedures.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: